{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:15:46Z","timestamp":1790349346354,"version":"4.1.0"},"reference-count":61,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pharmaceutical advancements and an improved understanding of pathophysiology have enabled innovative therapies for chronic conditions like dyslipidemia. This condition is marked by abnormalities in lipid homeostasis. Nucleic acid therapeutics, including antisense oligonucleotides and small interfering RNAs, are novel management strategies that silence genes by targeting mRNA. Antisense oligonucleotides modify mRNA to inhibit protein production, whereas small interfering RNAs induce mRNA degradation via the RNA-induced silencing complex (RISC), thus offering promising treatments for dyslipidemia and atherosclerotic cardiovascular disease. Chemical modifications improve their stability and mRNA targeting. RNA-based therapies targeting PCSK9, Lp(a), ApoC-III, and ANGPTL3 hold transformative potential for treating dyslipidemia effectively. This article discusses the latest data from completed and ongoing trials on RNA therapies for dyslipidemia, including inclisiran, pelacarsen, olpasiran, zerlasiran, lepodisiran, volanesorsen, olezarsen, plozasiran, zodasiran, and solbinsiran. Each therapy targets specific molecules while also significantly impacting other lipid parameters. The promising results of these trials indicate potential improvements in lipid therapy and cardiovascular risk reduction, with ongoing studies expected to further refine the role of the novel RNA-based agents in effective lipid management.<\/jats:p>","DOI":"10.3390\/ijms26031026","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T03:54:27Z","timestamp":1737950067000},"page":"1026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Novel RNA-Based Therapies in the Management of Dyslipidemias"],"prefix":"10.3390","volume":"26","author":[{"given":"Constantine E.","family":"Kosmas","sequence":"first","affiliation":[{"name":"2nd Department of Cardiology, National & Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D.","family":"Bousvarou","sequence":"additional","affiliation":[{"name":"Health Center of Sofades, 43300 Karditsa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8752-1869","authenticated-orcid":false,"given":"Donatos","family":"Tsamoulis","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology, National & Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gianniou","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Patras, 26504 Rio, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia J.","family":"Papakonstantinou","sequence":"additional","affiliation":[{"name":"General Directorate of Public Health and Social Welfare, Attica Region, 11521 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-0309","authenticated-orcid":false,"given":"Loukianos S.","family":"Rallidis","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology, National & Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A Modern Approach to Dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archinte.168.6.598","article-title":"Lipoprotein(a) levels and risk of future coronary heart disease: Large-scale prospective data","volume":"168","author":"Bennet","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration (2009). Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 302, 412\u2013423.","DOI":"10.1001\/jama.2009.1063"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: The EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kosmas, C.E., Bousvarou, M.D., Papakonstantinou, E.J., Tsamoulis, D., Koulopoulos, A., Uceta, R.E., Guzman, E., and Rallidis, L.S. (2023). Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a). Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713622"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/nat.2023.0068","article-title":"Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation","volume":"34","author":"Belgrad","year":"2024","journal-title":"Nucleic Acid. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"174178","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: Mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Barale, C., Melchionda, E., Morotti, A., and Russo, I. (2021). PCSK9 Biology and Its Role in Atherothrombosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115880"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pathol.2018.10.012","article-title":"PCSK9: From biology to clinical applications","volume":"51","author":"Blanchard","year":"2019","journal-title":"Pathology."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/eurheartj\/ehz566","article-title":"Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin\/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin\/kexin type-9","volume":"41","author":"Jang","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial","volume":"4","author":"Ray","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): Results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"ORION-9 Investigators. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: The ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, Safety, and Tolerability of Inclisiran in Patients with Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"key":"ref_21","unstructured":"(2024, November 05). A Study of Inclisiran to Prevent Cardiovascular Events in High-Risk Primary Prevention Patients. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05739383."},{"key":"ref_22","unstructured":"(2024, November 05). A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People with Cardiovascular Disease (ORION-4). Available online: https:\/\/clinicaltrials.gov\/study\/NCT03705234."},{"key":"ref_23","unstructured":"(2024, November 05). Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants with Established Cardiovascular Disease (VICTORION-2P). Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05030428."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sosnowska, B., Surma, S., and Banach, M. (2022). Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy. Pharmaceuticals, 15.","DOI":"10.3390\/ph15121573"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11883-019-0792-8","article-title":"Antisense Oligonucleotides Targeting Lipoprotein(a)","volume":"21","author":"Langsted","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_27","unstructured":"(2024, November 07). ClinicalTrials.gov Identifier: NCT04023552. Assessing the Impact of Lipoprotein (a) Lowering with Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients with CVD [Lp(a)HORIZON]. Available online: https:\/\/clinicaltrials.gov\/study\/NCT04023552."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"Rosenson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_29","unstructured":"(2024, November 10). ClinicalTrials.gov Identifier: NCT05581303. A Double-Blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a). Available online: https:\/\/clinicaltrials.gov\/study\/NCT05581303."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals with Elevated Plasma Lipoprotein(a) Levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"ref_33","unstructured":"(2024, November 11). A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults with Elevated Lipoprotein(a). Available online: https:\/\/clinicaltrials.gov\/study\/NCT05565742."},{"key":"ref_34","unstructured":"(2024, November 11). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event\u2013ACCLAIM-Lp(a). Available online: https:\/\/clinicaltrials.gov\/study\/NCT06292013."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11883-023-01080-8","article-title":"APOC-III: A Gatekeeper in Controlling Triglyceride Metabolism","volume":"25","author":"Giammanco","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tem.2020.11.005","article-title":"Lipoprotein Lipase and Its Regulators: An Unfolding Story","volume":"32","author":"Wu","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14779072.2021.1955348","article-title":"Volanesorsen for treatment of familial chylomicronemia syndrome","volume":"19","author":"Lazarte","year":"2021","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"COMPASS study group. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Alexander","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacl.2023.03.007","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial","volume":"17","author":"Witztum","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e13841","DOI":"10.1111\/eci.13841","article-title":"Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials","volume":"52","author":"Calcaterra","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study","volume":"16","author":"Oral","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","article-title":"Volanesorsen: First Global Approval","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"key":"ref_44","unstructured":"(2024, November 16). Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA. Available online: https:\/\/ir.ionis.com\/news-releases\/news-release-details\/akcea-and-ionis-receive-complete-response-letter-waylivra-fda."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Bridge\u2013TIMI 73a Investigators. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Balance Investigators. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_48","unstructured":"(2024, November 20). Olezarsen Receives Orphan Drug Designation from U.S. FDA for Familial Chylomicronemia Syndrome. Available online: https:\/\/ir.ionis.com\/news-releases\/news-release-details\/olezarsen-receives-orphan-drug-designation-us-fda-familial."},{"key":"ref_49","unstructured":"(2024, November 20). A Study of Olezarsen Administered Subcutaneously to Participants with Severe Hypertriglyceridemia. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05552326."},{"key":"ref_50","unstructured":"(2024, November 20). A Study of Olezarsen (ISIS 678354) Administered to Participants with Severe Hypertriglyceridemia. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05079919."},{"key":"ref_51","unstructured":"(2024, November 20). A Study of Olezarsen (ISIS 678354) in Participants with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or with Severe Hypertriglyceridemia. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05610280."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_54","unstructured":"(2024, November 20). A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome. Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05089084."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk","volume":"392","author":"Watts","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_56","first-page":"49","article-title":"Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia","volume":"14","author":"Kosmas","year":"2022","journal-title":"Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"ARCHES-2 Trial Team. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_58","unstructured":"(2024, November 21). Study of ARO-ANG3 in Participants with Homozygous Familial Hypercholesterolemia (HOFH) (Gateway). Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05217667."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"A12705","DOI":"10.1161\/circ.148.suppl_1.12705","article-title":"Identification and Characterization of Solbinsiran, a GalNAc Conjugated siRNA Targeting Angiopoietin-Like 3","volume":"148","author":"Dudek","year":"2023","journal-title":"Circulation"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0735-1097(24)03663-5","article-title":"Solbinsiran, a galnac-conjugated sirna targeting angptl3, reduces atherogenic lipoproteins in individuals with mixed dyslipidaemia in a durable and dosedependent manner","volume":"83","author":"Ray","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_61","unstructured":"(2024, November 21). A Study of LY3561774 in Participants with Mixed Dyslipidemia (PROLONG-ANG3). Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05256654."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:01Z","timestamp":1759919761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26031026"],"URL":"https:\/\/doi.org\/10.3390\/ijms26031026","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]}}}